US Stock Market Move | ZAI LAB (ZLAB.US) rises more than 8% as FDA approves pre-filled subcutaneous injection of agamodin.

On Monday, ZAI LAB's stock rose over 13% at one point during trading, and as of press time, it had risen over 8% to $32.09 per share. In terms of news, on April 11th, ZAI LAB's partner argenx announced that the U.S. Food and Drug Administration (FDA) had officially approved the pre-filled subcutaneous injection form of efgartigimod for the treatment of adult patients with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) and adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). ZAI LAB stated that they plan to submit an application for the approval of the pre-filled subcutaneous injection form of efgartigimod in China by 2025.